PenderFund Capital Management’s Blueprint Medicines BPMC Stock Holding History

PenderFund Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,200	Closed	-$282K	–	212
2025 Q2	$282K	Buy	+2,200	New	+$229K	0.07%	79

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PenderFund Capital Management's BPMC Position: Q3 2025 in Review

PenderFund Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,200 shares — an estimated $282K sold.

PenderFund Capital Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $282K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

PenderFund Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
PenderFund Capital Management sold 2,200 Blueprint Medicines shares in Q3 2025, an estimated $282K.
PenderFund Capital Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
PenderFund Capital Management's Blueprint Medicines position peaked at $282K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on PenderFund Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.